

Figure 7.

Epicortical recording of ictal electroencephalography (EEG) with subdural electrodes during a habitual seizure in Patient 2. This particular seizure (only aura and nonmotor seizure) occurred when the patient was talking to the family while sitting on the bed. With the onset of the ictal pattern, the patient lay on the bed and stopped talking, and no movements were observed. Seven seconds after the end of seizure pattern, the patient quickly sat on the bed again. By the interview after the seizure, it was confirmed that the patient had a habitual aura, and could not speak or move at all immediately after the onset of aura until it had gone. All of the ictal EEG patterns started as 8–12 Hz rhythmic activities commonly involving three electrodes (A6, A7, and C14) placed rostral to the precentral sulcus just over the cystic lesion, and additionally at A8, A15, and A16 always before onset of tonic seizures by 4–34 s (average of 14 s).

Epilepsia © ILAE




Figure 8.

Scalp-recorded interictal epileptiform discharges in Patient 3. During sleep period, the patient had small, but consistent spikes (labeled by filled triangles) at the vertex (max at Cz), which at times occurred as short runs of 3–5 s. (AV, average reference.)

Epilepsia © ILAE

In clinical neurology, the term “apraxia” is applied to a state in which a clear-minded patient with no weakness, ataxia, or other extrapyramidal derangement, and no

defect of the primary modes of sensation, loses the ability to execute highly complex and previously learned skills and gestures (Ropper & Brown, 2005), and it even

Table 2. Comparison of clinical features between ictal paresis and NMS arrest of movements in the present study

	Loss of muscle tone or weakness	Ictal focus	Reference
Ictal paresis			
Ictal hemiplegia /monoparesis	+	SI/MI	Gowers, 1885 Matsumoto et al., 2005 Villani et al., 2006
Inhibitory seizures	+	SI	Abou-Khalil et al., 1995
Focal atonic/akinetic seizure	+		Gastaut & Broughton, 1972
	+	PNMA?	So, 1995
	+	NMA?	Noachtar & Lüders, 1999
NMS arrest of movements	-	Mesial premotor NMA	Meletti et al., 2003 The present study

PNMA, primary negative motor area; NMA, negative motor area; MI, primary motor area; SI, primary somatosensory cortex; NMS, negative motor seizure. [Correction added after online publication 20 May 2009: Ictal focus and Reference moved to top of columns]

Table 3. Comparison of proposed symptoms among epileptic interference, epileptic activation, and epileptic inactivation

Cortical areas	Epileptic interference	Epileptic activation	Epileptic inactivation
MI		Convulsion, myoclonus	Paralysis, negative myoclonus
SI		Hyperesthesia	Sensory defects
Primary visual area		Elementary visual hallucination	Scotoma
Auditory cortices		Tinnitus, auditory hallucination	Deafness
SMA proper		Tonic convulsion	Proximal weakness
SII		Pain, hyperesthesia	
Frontal eye field		Contralateral version	
Speech area	Aphasia		
SNMA (pre-SMA)	NMS	(negative myoclonus)	
PNMA (Brodmann's 44)	NMS		

MI, primary motor area; SI, primary somatosensory cortex; SMA, supplementary motor area; SII, second sensory area; SNMA, supplementary negative motor area; PNMA, primary negative motor area; NMS, negative motor seizure. [Correction added after online publication 20 May 2009: Aphasia, NMS, NMS moved under Epileptic interference column]

includes simple clumsiness. The latter can correspond to limb-kinetic apraxia. For the diagnosis of apraxia, it is important to determine whether spontaneous action or

reflexive action to the unexpected stimuli is preserved, whereas praxes or skilled movements (i.e., pantomime, tool utilization, and so on) are impaired. It is not practical to check this during NMS because the seizures are rather brief, and patients may not do due to distraction by the seizures. Therefore, it may not execute suitable to call the symptoms of NMS apraxia currently. In addition, the clinical findings of apraxia are usually described in patients with chronic lesion or degenerative disorders where the compensatory restorative network system is fully employed. By contrast, in the case of symptoms of NMS, ictal activity arising from NMA can be localized at NMA or can spread to the adjacent or remote area as a dynamic ictal activity, and thus a compensatory or a modifying mechanism occurring in chronic diseases is unlikely to be present. Namely, apraxia during seizures (ictal apraxia), if present, would manifest differently than in one with chronic diseases. Therefore, the possibility that the symptoms in NMS arising from NMA are defined as apraxia could not be completely excluded. The same situation is also considered in the NMR elicited by cortical stimulation of short duration such as 5 s.

Akinesia is characterized by poverty and slowness of initiation and execution of willed and associated movements, and difficulty in changing one motor pattern to another, in the absence of paralysis (Lakke, 1981). It is usually examined by the degree of delay in the time needed to initiate a movement, as a reaction time, being regarded as an impairment of the latter phase of program of voluntary movements by the basal ganglia and its related cortical networks (Watson et al., 1992; Imai, 1996). Narabayashi (1980) described three types of akinesia: akinesia due to marked rigidity of muscles, lack of movement initiation without rigidity due to striatal dopamine deficiency, and freezing or festination in quick repetitive movements due to impairment of rhythm formation. Arrest of motion and vocalization in the present three patients might represent akinesia at least, since it is defined without weakness. However, all types of akinesia in the previous definition are related to dysfunction of the basal ganglia system and its relevant central nervous system (CNS) structures. Furthermore, symptoms of NMS and NMR (i.e., arrest of ongoing voluntary movements) develop in several seconds immediately after seizure onset and after starting cortical stimulation, respectively, but they are not the problem at the beginning like akinesia. For these two reasons, by definition, akinesia would not be appropriate to describe the symptoms of NMS. Based on the preceding discussion, it is most likely that the patients' symptoms, that is, arrest of motion and vocalization, are best defined as NMS, because there are many commonalities to the NMR.

With regard to ictal speech arrest versus aphasia, inability to speak could occur as epileptic events while the consciousness is preserved, and it is explained by motor

aphasia (ictal aphasia) (Hamilton & Matthews, 1979) or symptoms of NMS. All three patients had speech arrest, and at least two patients had arrest or slowness of tongue movements. Their comprehension was apparently preserved, and thus their speech arrest might be interpreted as simply arrest of motion or buccofacial apraxia (De Renzi et al., 1966). Because it is known that buccofacial apraxia and aphasia occur together (De Renzi et al., 1966; Kertesz & Hooper, 1982), it is possible that they occurred in our patients together. However, since the seizure focus was very limited in the several electrodes when Patients 1 and 2 had those symptoms and since the possible epileptogenic area in Patient 3 was also small as revealed by T₂-weighted image, it is unlikely that our patients had both buccofacial apraxia and aphasia, but just so-called arrest of motion, similar to NMR elicited by cortical stimulation. As discussed previously, because buccofacial apraxia was described in patients with chronic diseases, the symptoms in NMS may not be identical to buccofacial apraxia, and thus it is best to describe this ictal symptom as NMS at this time.

Location and function of NMA

Lüders et al. (1995) described the two distinct areas that produced NMR with cortical electric stimulation, that is, supplementary NMA (SNMA) and primary NMA (PNMA). SNMA was located in the rostral part of or rostral to the SMA proper, and thus at least partly it corresponded to pre-SMA in humans. PNMA was located in the posterior part of the inferior frontal gyrus, just rostral to the precentral sulcus, and thus it would be a part of the area 44 in the Brodmann's map.

In addition to those two areas, NMA was also described rostral to the precentral sulcus along it, such as in the middle frontal gyrus, and even in the lateral convexity of the superior frontal gyrus (Nii et al., 1996; Mikuni et al., 2006). In the present study, Patient 1 had ictal discharges on the mesial frontal cortex just along the line on the anterior commissure vertical to AC-PC line (VAC) and spread to the posterior part, but its anterior part was completely occupied by the tumor, and thus the pre-SMA could be dislocated posterior to it. In Patient 2, five electrodes of NMA were located in the superior frontal gyrus, but the most lateral and posterior one (A7) was located just 1–2 cm anterior to the positive motor area of the hand as shown in Fig. 2. Because the cystic lesion was present beneath or directly adjacent to the area (A7 in Fig. 6), the normal somatotopy should be distorted, and thus it is likely that the lateral NMA in Patient 2 (A7, A8 in Fig. 6) was identified as ones along the precentral sulcus in the high, lateral convexity as shown previously, being independent of pre-SMA (Nii et al., 1996; Mikuni et al., 2006). In Patient 3, since EEG and MRI both suggested abnormality in the vertex area, the symptoms were interpreted as the dysfunction of the pre-SMA.

In the recent cytoarchitectural study in animals, Matelli et al. (1991) labeled the rostral SMA as F6, which receives connection from the thalamic inputs (from the nucleus ventralis anterior and pars parvocellularis), F5 (area 44), and various prefrontal regions. F6 lacks corticospinal pathways, and those features are totally different from the caudal part of the SMA (F3 in monkeys and SMA proper in humans). F5 was defined in area 44 in the lateral frontal cortex, and it shares features similar to F3. Abundant connections from F5 to F3 have been described (Rizzolatti et al., 1988; Rizzolatti & Craighero, 2004). Because NMA is one of the most important generators of Bereitschaftspotentials (BPs) (Yazawa et al., 2000; Ikeda, 2003; Ikeda & Shibasaki, 2003; Kunieda et al., 2004), it is probably employed for the organization and integration of fine motor movements, and thus the activation of this area by high-frequency electric stimulation would produce impairment of fine movements (called "apraxia" by Lüders et al., 1995).

NMS versus NMR

A direct comparison between NMS in ictal semiology and NMR in cortical stimulation in the same patient was very difficult in the clinical documentation. In Patient 1, extensive cortical stimulation was not possible due to seizure induction; in Patient 2, NMS was too brief to be examined in detail during video-EEG monitoring. Nevertheless, as shown in the result, ictal semiologies commonly observed, at least in the two patients, are listed in the order of appearance, as (1) indescribable or ill-localized aura, (2) repetitive involuntary vocalization, (3) inability to speak, (4) inability to move the extremities, and (5) subsequent evolution to positive motor seizures. Awareness and comprehension were preserved throughout the episode before generalized seizures (Table 1). Those ictal semiologies fit well the results of cortical functional mapping made by high-frequency electric cortical stimulation including NMR. A similar, but a rather inverse sequence of ictal semiology was also reported in a patient having the mesial frontal lesion with scalp EEG and polygraphic analysis (Meletti et al., 2003).

Repetitive vocalization is often produced by high-frequency cortical stimulation in the face area in the SMA proper (Lim et al., 1994), that is, the rostral part of the SMA proper. In Patient 1, the initial ictal activity started in the mesial frontal area (A2) along the VAC line. A similar interpretation is also possible in Patient 3, even though she did not undergo invasive EEG monitoring. Because the SNMA is usually located anterior to the SMA proper, that is, anterior to the VAC line, it is conceivable that once ictal activity starts in the rostral part of the SMA proper, it then spreads further into the anterior part (pre-SMA or SNMA). In Patient 3, at the beginning of the seizures the patient had involuntary repetitive vocalization, followed

by inability to speak out and mild awkward movements of the right hand.

NMS versus ictal paresis

Focal seizures with ictal paresis or paralysis of one or more parts of the body were called focal akinetic seizures by Noachtar and Lüders, who discussed the area responsible as being in the NMA (Noachtar & Lüders, 1999). Focal akinetic seizures belongs to "inhibitory motor seizures" among focal motor seizures in the proposed international classification of epilepsy and seizures in 2001 as well as in the Report of the International League Against Epilepsy (ILAE) Classification Core Group (Engel, 2001, 2006). Recent reports have showed that focal inhibitory seizures were also associated with ictal activity in the primary motor and somatosensory cortices (Abou-Khalil et al., 1995; Matsumoto et al., 2005), that is entirely different from arrest of motion reported in the present study. The present study clearly showed that NMA is an area responsible for seizures manifesting ictal arrest of motion and vocalization, and thus we want to call it NMS, following the term of NMA.

In Patient 3, very mild weakness in the proximal part was observed in the right stretched hand during bilateral hand raising test, although not in all the seizures, but the tonus of the upper extremities was normal. It remains unresolved whether it was also explained by the ictal activity in the rostral SMA. Recently, Rubboli et al. (2006) described a so-called pure silent period in the contralateral deltoid muscle in the outstretched hand posture, producing clinically small jerks or loss of muscle tone when they stimulated the SMA with a single electric pulse stimulation of 1 Hz, like in the case of a part of primary sensorimotor cortex (Ikeda et al., 2000), but they did not observe motor evoked potentials or speech interruption. This may provide some clues that SMA can elicit contralateral, proximal weakness as seen in Patient 3, in addition to NMS from NMA. Because the number of patients was limited in the present study, it still remains to be established whether seizures from NMA also manifest focal ictal paresis in addition to NMS.

Rare incidence of NMS

In two patients (Patients 1 and 2), positive motor seizures subsequently occurred following NMS, and the two patients had a history of GTCS. Because these patients had frontal lobe epilepsy, it is very likely that ictal activity can spread easily to nonprimary and primary motor cortices, resulting in positive motor seizures, and subsequently GTCS.

NMS has rarely been described by video-EEG monitoring, although suspicious situations were documented in the literature before the development of video-EEG monitoring (Penfield & Jasper, 1954). NMS has never been precisely documented by invasive recording previously. It is

probably because even though NMS occurred, the patient would not recognize it unless he allows himself to do voluntary movements during this period, as in the case of NMR with high-frequency stimulation. Furthermore, once the ictal activity responsible for NMS spreads into the adjacent nonprimary or primary motor cortices, the positive motor symptoms would obscure NMS. Although ictal activity that elicits positive motor seizures can spread into the NMA, the symptoms of NMS could be hidden by positive motor symptoms, or arrest of motion could not be tested because the consciousness is disturbed. The patients are not cooperative due to anxiety, or arrest of motion could be misinterpreted as a postictal exhausted condition.

In conclusion, when ictal activity arises from the NMA of either mesial or lateral frontal cortices, arrest of motion and vocalization occur, even though the patient is aware and comprehension is preserved, and thus it is called NMS. Clear weakness or decreased muscle tonus is not present, but very slight proximal weakness may be associated, which would reflect one of the functions of the NMA as well. Since focal ictal activity within the NMA could quickly spread to the adjacent primary or nonprimary motor cortices, elicited positive motor symptoms can obscure NMS. The symptoms of NMS may reflect ictal apraxia in an acute dynamic state of ictus, but this requires further investigation.

ACKNOWLEDGMENTS

This study was supported by Grants-in-Aid for Scientific Research (C)(2) 18590935 from the Japan Society for the Promotion of Science (JSPS) and Research Grant for the Treatment of Intractable Epilepsy (19-1) from the Japan Ministry of Health, Labor and Welfare for A.I.

We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosure: None of the authors has any conflict of interest to disclose.

REFERENCES

- Abou-Khalil B, Fakhoury T, Jennings M, Moots P, Warner J, Kessler RM. (1995) Inhibitory motor seizures: correlation with centroparietal structural and functional abnormalities. *Acta Neurol Scand* 91:103-108.
- De Renzi E, Pieczuro A, Vignolo LA. (1966) Oral apraxia and aphasia. *Cortex* 2:50-73.
- Engel J Jr. (2001) ILAE commission report. A proposed diagnostic schema for people with epileptic seizures and with epilepsy: report of the ILAE task force on classification and terminology. *Epilepsia* 42:796-803.
- Engel J Jr. (2006) Report of the ILAE Classification Core Group. *Epilepsia* 47:1558-1568.
- Fisher CM. (1978) Transient paralytic attacks of obscure nature: the question of nonconvulsive seizure paralysis. *Can J Neurol Sci* 5:267-273.
- Gastaut H, Broughton R. (1972) *Epileptic seizures*. Charles C Thomas, Springfield.
- Gowers WR. (1885) *Epilepsy and other chronic convulsive diseases*. Williams Woods, New York.
- Guerrini R, Dravet C, Genton P, Bureau M, Roger J, Rubboli G, Tassinari CA. (1993) Epileptic negative myoclonus. *Neurology* 43:1078-1083.

- Hamilton NG, Matthews T. (1979) Aphasia: the sole manifestation of focal status epilepticus. *Neurology* 29:745–748.
- Hirasawa K, Muragaki Y, Yamane F, Hori T, Ikeda A, Ohara S. (2001) A case of mesial frontal glioma with ictal arrest of motions arising from the supplementary motor area. *J Jpn Epil Soc* 19:60. (abstract in Japanese).
- Ikeda A, Lüders HO, Burgess RC, Shibasaki H. (1992) Movement-related potentials recorded from supplementary motor area and primary motor area: role of supplementary motor area in voluntary movements. *Brain* 115:1017–1043.
- Ikeda A, Yazawa S, Kunieda T, Araki K, Aoki T, Hattori H, Taki W, Shibasaki H. (1997) Scalp-recorded focal, ictal DC shift in a patient with tonic seizure. *Epilepsia* 38:1350–1354.
- Ikeda A, Taki W, Kunieda T, Terada K, Mikuni N, Nagamine T, Yazawa S, Ohara S, Hori T, Kaji R, Kimura J, Shibasaki H. (1999) Focal ictal DC shifts in human epilepsy as studied by subdural and scalp recording. *Brain* 122:827–838.
- Ikeda A, Ohara S, Matsumoto R, Kunieda T, Nagamine T, Miyamoto S, Kohara N, Taki W, Hashimoto N, Shibasaki H. (2000) Role of primary sensorimotor cortices in generating inhibitory motor response in humans. *Brain* 123:1710–1721.
- Ikeda A. (2003) Electrooculography in motor control and movement disorders. In Hallett M (Ed.) *Handbook of Clinical Neurophysiology: Movement Disorders*. Elsevier, Amsterdam, pp. 31–44.
- Ikeda A, Shibasaki H. (2003) Intracranial recording of Bereitschaftspotentials in patients with epilepsy. In Jahanshahi J, Mallett M (Eds) *The Bereitschaftspotentials: Movement-related cortical potentials*. Kluwer Academic/Plenum, New York, pp. 45–59.
- Imai H. (1996) Clinicophysiological features of akinesia. *Eur Neurol* 36(Suppl. 1):9–12.
- Kertesz A, Hooper P. (1982) Praxis and language: the extent and variety of apraxia in aphasia. *Neuropsychologia* 20:275–286.
- Kirshner HS, Hughes T, Fakhoury T, Abou-Khalil B. (1995) Aphasia secondary to partial status epilepticus of the basal temporal language area. *Neurology* 45:1616–1618.
- Kunieda T, Ikeda A, Ohara S, Matsumoto R, Taki W, Hashimoto N, Baba K, Inoue Y, Mihara T, Yagi K, Shibasaki H. (2004) Role of the lateral non-primary motor area in humans as revealed by Bereitschaftspotential. *Exp Brain Res* 156:135–148.
- Lakke PWF (Chairman of ad hoc Committee on Classification). (1981) Classification of extrapyramidal disorders. *J Neurol Sci* 51:311–327.
- Lim SH, Dinner DS, Pillay PK, Lüders H, Morris HH, Klem G, Wyllie E, Awad IA. (1994) Functional anatomy of the human supplementary sensorimotor area: results of extraoperative electrical stimulation. *Electroencephalogr Clin Neurophysiol* 91:179–193.
- Lüders H, Lesser RP, Dinner DS, Morris HH, Hahn JF, Friedman L, Skipper G, Wyllie W, Friedman D. (1987) Commentary: chronic intracranial recording and stimulation with subdural electrodes. In Engel J Jr (Ed.) *Surgical treatment of the epilepsies*. Raven Press, New York, pp. 297–321.
- Lüders HO, Dinner DS, Morris HH, Wyllie E, Comair YG. (1995) Cortical electric stimulation in humans: the negative motor areas. In Fahn S, Hallett M, Lüders HO (Eds) *Negative motor phenomena. Advances in Neurology*, vol. 67. Lippincott-Raven, New York, pp. 115–1129.
- Matelli M, Luppino G, Rizzolatti G. (1991) Architecture of superior and mesial area 6 and the adjacent cingulate cortex in the macaque monkey. *J Comp Neurol* 311:445–462.
- Matsumoto R, Ikeda A, Hitomi T, Aoki T, Miki Y, Tomimoto H, Shimohama S, Shibasaki H. (2005) Ictal monoparesis associated with lesion in the primary somatosensory area. *Neurology* 65:1476–1478.
- Meletti S, Rubboli G, Testoni S, Michelucci R, Cantalupo G, Stanzani-Maserati M, Calbucci F, Tassinari CA. (2003) Early ictal speech and motor inhibition in fronto-mesial epileptic seizures: a polygraphic study in one patient. *Clin Neurophysiol* 114:56–62.
- Mikuni N, Ohara S, Ikeda A, Hayashi N, Nishida N, Taki J, Enatsu R, Matsumoto R, Shibasaki H, Hashimoto N. (2006) Evidence of a wide distribution of negative motor areas in the perirolandic cortex. *Clin Neurophysiol* 117:33–40.
- Mikuni N, Okada T, Takin J, Matsumoto R, Nishida N, Enatsu R, Hanakawa T, Ikeda A, Miki Y, Urayama S, Fukuyama H, Hashimoto N. (2007) Fibers from the dorsal premotor cortex elicit motor evoked potential in a cortical dysplasia. *Neuroimage* 34:12–18.
- Narabayashi H. (1980) Clinical analysis of akinesia. *J Neural Transm Suppl* 16:129–136.
- Nii Y, Uematsu S, Lesser RP, Gordon B. (1996) Does the central sulcus divide motor and sensory functions? Cortical mapping of human hand areas as revealed by electrical stimulation through subdural grid electrodes. *Neurology* 46:360–367.
- Noachtar S, Lüders HO. (1999) Focal akinetic seizures as documented by electroencephalography and video recording. *Neurology* 53:427–429.
- Noachtar S, Lüders HO. (2000) Akinetic seizures. In Lüders HO, Noachtar S (Eds) *The Epileptic Seizures: Pathophysiology and Semiology*. Churchill Livingstone, New York, pp. 489–500.
- Penfield W, Rasmussen T. (1950) *The cerebral cortex of man. a clinical study of localization of function*. MacMillan Company, New York.
- Penfield W, Jasper H. (1954) *Epilepsy and the functional anatomy of the human brain*. Little, Brown, Boston.
- Rizzolatti G, Camarda R, Fogassi L, Gentilucci M, Luppino G, Matelli M. (1988) Functional organization of inferior area 6 in the macaque monkey. II. Area F5 and the control of distal movements. *Exp Brain Res* 71:491–507.
- Rizzolatti G, Craighero L. (2004) The mirror-neuron system. *Annu Rev Neurosci* 27:27–47.
- Ropper AH, Brown RH. (2005) *Adams and Victor's Principles of Neurology*. 8th ed. McGraw-Hill, New York.
- Rubboli G, Mai R, Meletti S, Francione S, Cardinale F, Tassi L, Lo Russo G, Stanzani-Maserati M, Cantalupo G, Tassinari CA. (2006) Negative myoclonus induced by cortical electrical stimulation in epileptic patients. *Brain* 129:65–81.
- Salanova V, Andermann F, Rasmussen T, Olivier A, Quesney LF. (1995) Parietal lobe epilepsy. Clinical manifestations and outcome in 82 patients treated surgically between 1929 and 1988. *Brain* 118:607–627.
- So NK. (1995) Atonic phenomena and partial seizures, a reappraisal. In Fahn S, Hallett M, Lüders HO (Eds) *Negative motor phenomena. Advances in Neurology*, vol. 67. Lippincott-Raven, New York, pp. 29–39.
- Villani F, D'Amico D, Pincherle A, Tullo V, Chiapparini L, Bussone G. (2006) Prolonged focal negative motor seizures: a video-EEG study. *Epilepsia* 47:1949–1952.
- Watson RT, Gnzales Rothi LJ, Heilman KM. (1992) Apraxia: a disorder of motor programming. In Joseph AB, Young RR (Eds) *Movement disorders in Neurology and Neuropsychiatry*, Chapter 87, Blackwell, Boston, pp. 681–695.
- Yazawa S, Ikeda A, Kunieda T, Ohara S, Mima T, Nagamine T, Taki W, Hori T, Shibasaki H. (2000) Human pre-supplementary motor area is active before voluntary movement: subdural recording of Bereitschaftspotentials from mesial frontal cortex. *Exp Brain Res* 131:165–177.

Cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia

Yoko Okamoto^a, Masafumi Ihara^a, Youshi Fujita^a, Hidefumi Ito^a,
Ryosuke Takahashi^a and Hidekazu Tomimoto^b

Cortical microinfarcts are reported in Alzheimer's disease, but not in subcortical vascular dementia; the disease specificity of cortical microinfarcts therefore remains unclear. The distribution of cortical microinfarcts in Alzheimer's disease ($n=8$) and subcortical vascular dementia ($n=6$) was analyzed. Cortical microinfarcts were frequently detected in Alzheimer's disease, whereas they were rarely observed in subcortical vascular dementia. In Alzheimer's disease, cortical microinfarcts were present predominantly in the occipital lobe, the area of predilection for amyloid angiopathy, and also in the vascular borderzone. Cortical microinfarcts were invariably located very close to amyloid β -deposited vessels with intercellular adhesion molecule-1 expression. These results indicate that cortical microinfarcts are caused by the

pathomechanism related to Alzheimer's disease, most likely to amyloid angiopathy. *NeuroReport* 20:990–996
© 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.

NeuroReport 2009, 20:990–996

Keywords: Alzheimer's disease, amyloid angiopathy, cortical microinfarct, subcortical vascular dementia

^aDepartment of Neurology, Graduate School of Medicine, Kyoto University, Kyoto and ^bDepartment of Neurology, Graduate School of Medicine, Mie University, Mie, Japan

Correspondence to Dr Yoko Okamoto, Department of Neurology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan
Tel/fax: +81 75 751 3766; e-mail: yoko416@kuhp.kyoto-u.ac.jp

Received 14 March 2009 accepted 17 April 2009

Introduction

Recently, an increasing body of evidence has indicated that vascular risk factors, such as hypertension and diabetes mellitus have a pivotal role in the pathogenesis of Alzheimer's disease [1]. Accordingly, the Nun study has shown that the risk of dementia increases more than 20 times in Alzheimer's disease, if the patients have foci of cerebral infarctions [2]. Cortical microinfarcts were predominantly observed in the vascular borderzone of Alzheimer's disease brains [3], and were found to be a strong determinant for dementia, in a manner comparable with the neuropathological hallmarks that determine Alzheimer's disease [4–6].

The pathoetiology and disease specificity of cortical microinfarcts remain elusive. It is unclear whether cortical microinfarcts are present exclusively in Alzheimer's disease brains, or are associated with hypertensive small-vessel disease. In this study, we compared the distribution of cortical microinfarcts in Alzheimer's disease and subcortical vascular dementia, focusing especially on their spatial correlation with amyloid angiopathy.

Materials and methods

Human tissue

Two hundred and seventy autopsied brains were obtained from the Kyoto University Hospital and its affiliated hospitals from 1988 to 2007 through a process approved by an institutional research committee. Among the 270 brains, there included 13 Alzheimer's disease brains and six subcortical vascular dementia brains. We excluded five

Alzheimer's disease brains because of concomitant macroscopic cerebral infarctions. We examined the remaining eight Alzheimer's disease brains (mean \pm SEM: 79 ± 4 years old) and six subcortical vascular dementia brains (mean \pm SEM: 77 ± 5 years old). These Alzheimer's disease and subcortical vascular dementia patients met the diagnostic criteria for dementia (*Diagnostic and Statistical Manual of Mental Disorders*, fourth edition) [7]. The diagnosis of Alzheimer's disease was based on the Consortium to Establish a Registry for Alzheimer's Disease diagnostic neuropathologic criteria [8], and the Braak and Braak neuropathological staging of Alzheimer-related changes [9].

The diagnosis of subcortical vascular dementia was made clinicopathologically to meet the criteria of: (i) the presence of bilateral diffuse subcortical lesions, (ii) lacunar infarctions in the perforator territory, (iii) arteriolosclerosis, such as fibrohyalinosis and fibrinoid necrosis, and (iv) the absence of cortical infarctions, and the clinical criteria outlined by Bennett *et al.* [10]. Cases with significant pathological hallmarks of Alzheimer's disease (senile plaque Braak stage \geq B, neurofibrillary tangle Braak stage \geq II [9]) were excluded.

Immunohistochemical staining

Tissue blocks obtained from the frontal, temporal, parietal, and occipital lobes were embedded in paraffin. Histological assessment was carried out with hematoxylin and eosin (H&E), Klüver–Barrera, and modified Bielschowsky staining. The rest of the blocks were used for immunohistochemistry as described earlier [11]. The

primary antibodies consisted of: rabbit anti-gial fibrillary acidic protein (GFAP) (diluted 1:200; Dako, Glostrup, Denmark), mouse anti-human cluster of differentiation 68 (CD68) (1:100; Dako), mouse anti-amyloid β -protein (1:100; Novocastra, Newcastle, UK), and mouse anti-intercellular adhesion molecule-1 (ICAM-1) (1:100; Santa Cruz Biotechnology, Santa Cruz, California, USA). For IgG, horseradish peroxidase-labeled anti-human IgG (1:50; Dako), and for actin, rhodamin-labeled phalloidin (1:200; Invitrogen Corporation, Carlsbad, California, USA) were used.

Image analysis

Images of the histological slides were captured with a digital camera (CAMEDIA C-7070; Olympus, Tokyo, Japan) and scanned (Canon, CanoScan N1220U; Canon Inc., Tokyo, Japan). In each slide, cortical areas were outlined and the corresponding numbers of pixels were counted using the ImageJ software package (National Institute of Health; Bethesda, Maryland, USA).

Definition and count of cortical microinfarcts

Cortical microinfarcts had not been defined earlier, and were therefore determined according to the following criteria: a cortical lesion that was not noticeable until examined microscopically and accompanied by a group of astrocyte or microglia/macrophage proliferation. Histological changes likely to be expanded Virchow-Robin spaces, microabscesses, or cortical laminar necrosis were excluded.

After measuring the number of microinfarcts and the cortical area in each specimen, we calculated the number of cortical microinfarcts (per cm^2) infiltrated by numerous GFAP-positive astrocytes or CD68-positive microglia/macrophages.

The cerebral cortex was divided into five regions according to the arterial supply of anterior, middle, and posterior cerebral arteries, and their two borderzones (anterior-middle and middle-posterior), based on the text atlas [12]. The borderzone was defined as the area within 3 cm apart from the proposed borderline [12], and the number of microinfarcts was calculated similarly as stated above. The distribution of microinfarcts was further studied in terms of their topographic relationships to the cortical layers and the cerebral convolutions. Briefly, microinfarcts were classified into those distributed in layers 1–3 or 4–6, or alternatively, into those located in the crown part, the sulcal part, or the depth of the sulcal part.

The topographical relationship between $A\beta$ -positive vessels and microinfarcts was also assessed. Microinfarcts were judged to adjoin $A\beta$ -deposited vessels, if they were localized within 1 mm of these vessels. Senile plaque load was assessed with modified Bielschowsky staining in the region containing each microinfarct. The severity of senile plaque load was divided into four groups: those with none, sparse, moderate, and frequent in accordance with the Consortium to Establish a Registry for Alzheimer's Disease criteria [8].


Statistical analysis

Data were statistically analyzed using one-way analysis of variance, followed by Bonferroni's post-hoc test (Statview version 5.0, SAS Institute, Cary, North Carolina, USA).

Results

All microinfarcts detected in H&E stains were invariably accompanied by GFAP-positive astroglia. The mean diameter of the microinfarcts was approximately $200\ \mu\text{m}$ (range 100–500). Cortical microinfarcts were found in all

Fig. 1



Photomicrographs of cortical microinfarcts with (a–c) and without microglial activation (d–f). The upper panels (a–c) and lower panels (d–f) are adjacent sections. Hematoxylin and eosin staining (a, d), immunohistochemistry for glial fibrillary acidic protein (GFAP; b, e), and cluster of differentiation 68 (CD68; c, f). Bars indicate $300\ \mu\text{m}$.

eight Alzheimer's disease brains and one of the six subcortical vascular dementia brains, and were classified into two groups: microinfarcts with or without infiltration of CD68-positive microglia/macrophages (Fig. 1). The lesions that had been infiltrated both by astroglia and microglia/macrophages were considered to be relatively recent infarcts. The lesions with astrogliosis, but without CD68-positive microglia/macrophages, were considered to be older. This is because both astroglia and microglia/macrophages are activated in the acute stage of cerebral infarction, but macrophages regress within several months.


In H&E stains, lesions accompanied by erythrocytes or hemosiderin depositions were excluded. Furthermore, Perls–Stieda staining was added to search for iron

deposits and IgG immunohistochemistry for serum protein extravasation, so that microhemorrhagic lesions could be ruled out. Only a minority (3%) of cortical microlesions were accompanied by iron deposits or IgG-positive astroglia, indicating that most microlesions are not caused by hemorrhagic mechanisms (compare Fig. 2a and c, and Fig. 2b and d).

The numerical densities of cortical microinfarcts with GFAP-positive astroglia in Alzheimer's disease were 0.45, 0.14, 0.43, and 1.08 (per cm²) in the frontal, temporal, parietal, and occipital lobes, respectively. The densities of cortical microinfarcts with CD68-positive microglia/macrophages were 0.11, 0.04, 0.00, and 0.44, respectively, in each lobe (Table 1 and Fig. 3a). In contrast, in subcortical vascular dementia, the numerical densities of cortical microinfarcts with GFAP-positive astroglia were 0.058, 0.015, 0, and 0, respectively, in each lobe (per cm²) (Table 1). Thus, cortical microinfarcts were frequent in Alzheimer's disease, but were rarely found in subcortical vascular dementia.

In Alzheimer's disease, there was a marginally significant increase of microinfarcts with GFAP-positive astroglia in the occipital lobe compared with the temporal lobe ($P = 0.0511$), whereas there was only an increased tendency compared with the other lobes (occipital vs. frontal, $P = 0.1709$; frontal vs. parietal, $P = 0.9775$; frontal vs. temporal, $P = 0.5118$). In terms of the arterial supply, the numerical densities of cortical microinfarcts with GFAP-positive astroglia were 0.40, 0.19, 0.28, 0.66, and 1.47 (per cm²) in Alzheimer's disease in the anterior, middle, and posterior cerebral arteries, anterior-middle cerebral arterial borderzone, and middle-posterior cerebral arterial borderzone, respectively (Table 1 and Fig. 3b). Most of the microinfarcts were distributed in the superficial borderzones. In terms of cortical layers, the number of microinfarcts with GFAP-positive astroglia was significantly different between the superficial and the deep

Fig. 2



Photomicrographs of cortical microinfarcts (CMIs) with immunohistochemical staining for IgG (a, c) and Perls–Stieda staining to detect iron depositions (b, d). Note IgG-positive astroglia (a) or iron deposits (b, inset). (c) and (d) show CMIs without IgG-positive glia or iron deposits, respectively. Bars in (a) indicate 250 μm, and in (b–d) 200 μm.

Table 1 The distribution of microinfarcts in different cortical regions

Number of cortical microinfarcts	Layer		Convolution ^a			AA	Lobe (per 1 cm ²) ^b					Vascular territory (per 1 cm ²) ^c					SP ^d		
	1–3	4–6	C	S	D	(+)	F	T	P	O	A	A/M	M	M/P	P	N	S	M	F
AD (n=8)																			
HE	40	9	25	1	23	26/49	0.28	0.08	0.20	0.44	0.16	0.37	0.07	0.82	0.00	0	13	19	17
GFAP	73	19	42	8	42	46/92	0.45	0.14	0.43	1.08	0.40	0.66	0.19	1.47	0.28	0	25	42	25
CD68	15	5	10	0	10	16/20	0.11	0.04	0.00	0.44	0.07	0.21	0.02	0.68	0.00	0	9	11	0
SVD (n=6)																			
HE	4	0	1	1	2	0/4 (0%)	0.043	0.015	0	0	0	0.029	0	0	0.028	4	0	0	0
GFAP	5	0	2	1	2	0/5 (0%)	0.058	0.015	0	0	0	0.048	0	0	0.028	5	0	0	0
CD68	4	0	1	1	2	0/4 (0%)	0.043	0.015	0	0	0	0.029	0	0	0.028	4	0	0	0

AA, amyloid angiopathy; +, the rate of AA-positive cortical microinfarcts; AD, Alzheimer's disease; HE, hematoxylin and eosin; GFAP, glial fibrillary acidic protein; CD68, cluster of differentiation 68; SVD, subcortical vascular dementia.


^aC, crown part; D, depth; S, sulcal part.

^bF, frontal; O, occipital; P, parietal; T, temporal.

^cA, A/M, M, M/P, P denotes anterior, middle, and posterior cerebral arteries, and their borderzones, respectively.

^dF, frequent; M, moderate; N, none; S, sparse; SP, senile plaque.

Fig. 3



The density of cortical microinfarcts (CMIs/cm²) in each lobe (a) and vascular territories (b), and the number of CMIs in cortical layers (c) and inside the cerebral convolutions (d). ACA, MCA, PCA, A/M, M/P denote anterior, middle, and posterior cerebral arteries, and their borderzones, respectively. CD68, cluster of differentiation 68; GFAP, glial fibrillary acidic protein.

layers of the Alzheimer's disease brains (73 vs. 19, respectively, $P = 0.0080$ by one-way analysis of variance) (Table 1 and Fig. 3c). However, no trends were found in terms of spatial distribution within the cerebral convolution (Table 1 and Fig. 3d).

A β -immunoreactive vessels were observed in six cases of the eight Alzheimer's disease brains, but not in six subcortical vascular dementia brains. Interestingly, A β deposition was predominantly in the vessels apposed to microinfarcts (Fig. 4). Such vessels were tortuous or double-barrel in shape. Half of the cortical microinfarcts with GFAP-positive astroglia (46 out of the 92) were localized less than 1 mm apart from A β -positive vessels. ICAM-1 was preferentially expressed in the endothelial cells and vessel walls surrounding microinfarcts (Fig. 5a and b). Double labeling for ICAM-1 and actin showed that the vessels around microinfarcts commonly express ICAM-1 (Fig. 5c-e). The number of microinfarcts was not associated with senile plaque burden (Table 2).

Discussion


Sporadic cerebral amyloid angiopathy (CAA) is a state in which A β deposits in the cerebral vessels, and has been

strongly related with the presence of dementia [13]. Thal *et al.* [14,15] have reported two types of sporadic CAA: capillary CAA and classical CAA. In capillary CAA, A β deposits are present within capillaries; whereas in classical CAA, A β initially deposits at the outer basement membrane of the leptomeningeal and cortical arteries, and then within their smooth muscle layer [14,15]. As both the capillary and classical CAA pathologies were present in most of the brains with Alzheimer's disease, further investigation is required to know which of the two pathologies underlies cortical microinfarcts.

CAA is dormant during lifetime, whereas it leads to major cerebral hemorrhage (approximately 5–20%) or infarct in a subset of elderly patients [16]. As a facilitating factor, the ApoE $\epsilon 2$ and $\epsilon 4$ alleles are related to a higher risk for CAA or CAA-associated hemorrhage [14–16]. In this study, the ApoE genotype was not assessed; therefore, it remains unknown whether there is a relationship between ApoE genotype and cortical microinfarcts in Alzheimer's disease.


The occipital lobe is most commonly and severely affected in CAA [14–16]. In this study, GFAP-positive

Fig. 4



Photomicrographs of cortical microinfarcts with hematoxylin and eosin staining (a, c) and immunohistochemistry for A β (b, d). The upper panels (a, b) and lower panels (c, d) are adjacent sections. Arrows indicate microinfarcts. Bars in (a-d) indicate 250 μ m.

Fig. 5



Photomicrographs of immunohistochemistry for intercellular adhesion molecule-1 (ICAM-1) (a-c), actin (d), and double labeling for ICAM-1 and actin (e). Bars in (a), (c-e) indicate 100 μ m, and in (b) 200 μ m.

Table 2 The number of GFAP-positive or CD68-positive cortical microinfarcts and their associations with senile plaque burden

Cortical microinfarcts	Total number of cortical microinfarcts	SP			
		None	Sparse	Moderate	Frequent
GFAP-positive	92	0	25	42	25
CD68-positive	20	0	9	11	0

CD68, cluster of differentiation 68; GFAP, glial fibrillary acidic protein; SP, senile plaque.

cortical microinfarcts were far more numerous in Alzheimer's disease compared with subcortical vascular dementia, and showed occipital predominance (Table 1). In addition, microinfarcts were invariably located very close to A β -deposited vessels with ICAM-1 expression and/or severe morphological changes. In contrast, ICAM-1 was rarely detected in the vessels without A β deposition and those in quiescent conditions. A spatial association between microinfarcts and ICAM-1 positive vessels may indicate activation of cell adhesion mechanism and subsequent thrombosis because it is often upregulated in inflammatory states, such as atherosclerosis [17]. In correspondence with these findings, occipital predominance has also been revealed in the distribution of microbleeds, which are also attributed to CAA [18].

Microinfarcts were distributed not only in the occipital lobe, but also in the superficial borderzone, in accordance with the earlier study [3]. Predilection of microinfarcts in the borderzone territory suggests that hypoperfusion in these areas contributes to the pathogenesis of microinfarcts in addition to amyloid angiopathy. Borderzone territory is irrigated with a decreased perfusion pressure [19] and this may be a key factor in ameliorating A β deposition [20,21]. Intriguingly, Weller *et al.* [22] propose that lymphatic drainage along capillary and artery plays a significant role in drainage of A β from the brain, where pulsatile movement of vessels acts as a driving force. A β clearance along vascular walls might decrease as vessels stiffen with age, thereby causing CAA. Therefore, the observed predilection of microinfarcts may be at least partially explained by the insufficient pulsatile movement and augmented A β deposition in the borderzone area.

In an earlier study, this group has reported cortical microvascular changes in Alzheimer's disease and their absence in subcortical vascular dementia [11]. The capillary densities in Alzheimer's disease were significantly decreased with various morphological changes, such as tearing or narrowing of the cortical microvessels. Furthermore, Stopa *et al.* [23] have reported that smooth muscle actin is decreased in the arterioles even from the early stages of Alzheimer's disease. In contrast to the medullary arteries, which consistently show arteriosclerotic changes in the white matter, small vessel changes were

rarely found in the cerebral cortices of subcortical vascular dementia. Different patterns of small vessel changes in topographical distribution may consequently explain the clear distinction between Alzheimer's disease and subcortical vascular dementia in terms of cortical microinfarcts.

Conclusion

Cortical microinfarcts may be caused by the pathomechanism related to Alzheimer's disease, most likely to amyloid angiopathy.

Acknowledgements

The authors express their cordial gratitude to Dr Ahmad Khundakar for critical reading of the manuscript and Miss Nakabayashi for excellent technical assistance. This study is supported, in part, by the Mochida Memorial Foundation for Medical and Pharmaceutical Research (to M.I.).

References

- 1 Kalaria RN. Similarities between Alzheimer's disease and vascular dementia. *J Neurol Sci* 2002; **203**:204:29–34.
- 2 Snowden DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. *JAMA* 1997; **277**:813–817.
- 3 Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, *et al.* Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. *Stroke* 2002; **33**:1986–1992.
- 4 White L, Petrovitch H, Hardman J, Nelson J, Davis DG, Ross GW, *et al.* Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants. *Ann NY Acad Sci* 2002; **977**:9–23.
- 5 Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Michel JP, *et al.* Cortical microinfarcts and demyelination significantly affect cognition in brain aging. *Stroke* 2004; **35**:410–414.
- 6 Kövari E, Gold G, Herrmann FR, Canuto A, Hof PR, Bouras C, *et al.* Cortical microinfarcts and demyelination affect cognition in cases at high risk for dementia. *Neurology* 2007; **68**:927–931.
- 7 American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington DC: American Psychiatric Association; 1994.
- 8 Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, *et al.* The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology* 1991; **41**:479–486.
- 9 Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 1991; **82**:239–259.
- 10 Bennett DA, Wilson RS, Gilley DW, Fox JH. Clinical diagnosis of Binswanger's disease. *J Neurol Neurosurg Psychiatry* 1990; **53**:961–965.
- 11 Kitaguchi H, Ihara M, Saiki H, Takahashi R, Tomimoto H. Capillary beds are decreased in Alzheimer's disease, but not in Binswanger's disease. *Neurosci Lett* 2007; **417**:128–131.
- 12 Kretschmann HJ, Weinrich W. *Neuroanatomy and cranial computed tomography*. New York, USA: Thieme-Stratton Corp.; 1986.
- 13 Neuropathology Group of the Medical Research Council Cognitive Function and Aging Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. *Lancet* 2001; **357**:169–175.
- 14 Thal DR, Griffin W ST, de Vos R Al, Ghebremedhin E. Cerebral amyloid angiopathy and its relationship to Alzheimer's disease. *Acta Neuropathol* 2008; **115**:599–609.
- 15 Thal DR, Ghebremedhin E, Rüb U, Yamaguchi H, Tredici KD, Braak H. Two types of sporadic cerebral amyloid angiopathy. *J Neuropathol Exp Neurol* 2002; **61**:282–293.
- 16 Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. *Acta Neuropathol* 2005; **110**:345–359.
- 17 Braun M, Pietsch P, Schrör K, Braumann G, Felix SB. Cellular adhesion molecules on vascular smooth muscle cells. *Cardiovascular Research* 1999; **41**:395–401.

- 18 Pettersen JA, Sathiyamoorthy G, Gao FQ, Szilagyi G, Nadkarni NK, St George-Hyslop P, *et al*. Microbleed topography, leukoaraiosis, and cognition in probable Alzheimer disease from the Sunnybrook Dementia Study. *Arch Neurol* 2008; **65**:790–795.
- 19 Torvik A. The pathogenesis of watershed infarcts in the brain. *Stroke* 1984; **15**:221–223.
- 20 Ihara M, Kalaria RN. Amyloid- β and synaptic activity in mice and men. *Neuroreport* 2007; **18**:1205–1206.
- 21 Román GC, Kalaria RN. Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. *Neurobiol Aging* 2006; **27**:1769–1785.
- 22 Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic drainage of the brain and the pathophysiology of neurological disease. *Acta Neuropathol* 2009; **117**:1–14.
- 23 Stopa EG, Butala P, Salloway S, Johanson CE, Gonzalez L, Tavares R, *et al*. Cerebral cortical arteriolar angiopathy, vascular beta-amyloid, smooth muscle actin, Braak stage, and APOE genotype. *Stroke* 2008; **39**: 814–821.

Attenuation of proteolysis-mediated cyclin E regulation by alternatively spliced *Parkin* in human colorectal cancers

Kyoko Ikeuchi¹, Hiroyuki Marusawa^{1*}, Mikio Fujiwara¹, Yuko Matsumoto¹, Yoko Endo¹, Tomohiro Watanabe¹, Akio Iwai¹, Yoshiharu Sakai², Ryosuke Takahashi³ and Tsutomu Chiba¹

¹Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

²Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

³Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Parkin has a critical role in the ubiquitin-proteasome system as an E3-ligase targeting several substrates. Our recent finding that *Parkin*-deficient mice are susceptible to tumorigenesis provided evidence that *Parkin* is a tumor suppressor gene. Dysfunction of the *Parkin* gene is frequently observed in various human cancers, but the mechanism underlying the cell cycle disruption induced by *Parkin* dysfunction that leads to carcinogenesis is not known. Here, we demonstrated that *Parkin* expression in colonic epithelial cells is regulated in a cell cycle-associated manner. Epidermal growth factor (EGF) stimulation upregulated *Parkin* gene expression in human colon cells. Inhibition of the phosphoinositide 3-kinase [PI(3)K]-Akt-dependent pathways suppressed growth factor-induced *Parkin* expression. The expression of alternatively spliced *Parkin* isoforms with various deletions spanning exons 3–6 was detected in 18 of 43 (42%) human colorectal cancer tissues. Wild-type *Parkin* induced the degradation of cyclin E protein, but the alternatively spliced *Parkin* identified in colon cancers showed defective proteolysis of cyclin E. These findings indicate that *Parkin* expression is induced by growth factor stimulation and is involved in the cell cycle regulation of colon cells. Tumor-specific expression of alternatively spliced *Parkin* isoforms might contribute to enhanced cell proliferation through the attenuation of proteolysis-mediated cyclin E regulation in human colorectal cancers.

© 2009 UICC

Key words: Parkin; colorectal cancer; cyclin E; cell cycle; EGF

Parkin functions in the ubiquitin-proteasome system as an E3 ligase, facilitating the ubiquitination of target proteins.^{1–3} Parkin is developmentally regulated with induced expression during cell differentiation, and little to no expression in immature cells.⁴ Several putative candidate substrates of Parkin-mediated proteolysis have been identified, including α -synphilin, α -synuclein interacting protein, synphilin-1 and Pael-R.^{5,6} Recently, it was revealed that deficiency of *Parkin* potentiates the accumulation of cyclin E protein in cultured postmitotic neurons exposed to the glutamatergic excitotoxin kainate, suggesting that the cell cycle regulator, cyclin E, is a putative substrate of the Parkin ubiquitin ligase complex in neurons.⁷ Since *Parkin* was first identified as a gene implicated in autosomal recessive juvenile Parkinsonism, one form of familial Parkinson disease,⁸ attention has been focused on unveiling the role of Parkin in neurons. The expression and regulation of Parkin in epithelial cells as well as the role of Parkin in cell cycle regulation, however, has not been clarified.

A loss of heterozygosity within chromosomal region 6q25-q27 containing the *Parkin* gene is frequently observed in various human tumors, including ovarian,^{9–11} breast,¹² renal¹³ and lung cancers.^{14,15} In addition, the *Parkin* gene is frequently deleted in breast, ovarian and liver cancers.^{16–18} We recently demonstrated that *Parkin*-deficient mice lacking exon 3 of the *Parkin* gene developed hepatocellular carcinoma, whereas *Parkin*^{-/-} mice were neurologically normal with no obvious neuropathologic changes.¹⁹ Further, the loss of *Parkin* expression contributes to the overproliferation of hepatocytes leading to hepatomegaly, suggesting a critical role for Parkin in the regulation of hepatocyte proliferation.¹⁹ These observations suggest that *Parkin* has a role as a tumor suppressor and may be involved in cell cycle regulation in epithelial cells.

Deregulation of the cell cycle, specifically the G1 and S phases, is a hallmark of human cancers, and *cyclin E* amplification and overexpression are observed in various human cancers.²⁰ One thing to be noted is that cyclin E protein is accumulated in the tumor cells in a considerable proportion of colorectal cancers.²¹ On the basis of these observations, in the present study, we evaluated the regulation of *Parkin* gene expression in association with cell cycle regulation in colonic epithelial cells.

Material and methods

Cell culture and transfection

The human colorectal cancer cell lines, HT29, SW48 and kidney-derived 293T cell lines were maintained in Dulbecco's modified Eagle's medium (Gibco-BRL, Tokyo, Japan) containing 10% fetal bovine serum. The human colorectal cancer-derived LoVo cells were cultured in Ham's F12 (MP Biomedicals, Solon, OH) containing 10% fetal bovine serum. Plasmid transfection was performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol.

Plasmids and reagents

The expression plasmids pcDNA3-*Parkin* and pcDNA3- Δ -*Parkin* were described previously.² The expression plasmids pcDNA3-*Akt* and pcDNA3-*Akt* (AA), encoding the wild-type and dominant negative mutants of human *Akt* with substitution of Thr308 and Ser473 by Ala,²² respectively, were made by inserting the PCR-amplified cDNA fragment of human *Akt* sequences. Recombinant human epidermal growth factor (EGF) and hepatocyte growth factor (HGF) were obtained from Peprotech EC (London, UK). Mitogen-activated protein kinase kinase (MEK) inhibitor PD98059 and phosphoinositide 3-kinase [PI(3)k] inhibitor wortmannin were purchased from Promega (Madison, WI) and Sigma Chemical (St. Louis, MO), respectively. MG132 was obtained from Peptide Institute (Osaka, Japan). Small interference RNA (siRNA) duplexes composed of 21-nucleotide sense and antisense strand used for targeting *Parkin* were obtained from Invitrogen.

Additional Supporting Information may be found in the online version of this article.

Abbreviations: cdk, cyclin-dependent kinases; EGF, epidermal growth factor; HGF, hepatocyte growth factor; IBR, in-between Ring; MEK, mitogen-activated protein kinase kinase; MAPK, mitogen-activated protein kinase; PI(3)K, phosphoinositide 3-kinase; RING, really interesting new gene; RT-PCR, reverse transcription polymerase chain reaction; 18s rRNA, 18s ribosomal RNA; siRNA, small interference RNA; UBL, ubiquitin-like; UPD, unique Parkin domain.

Grant sponsor: Grants-in-aid for Scientific Research (The Ministry of Education, Culture, Sports, Science, and Technology of Japan); Grant numbers: 8209027, 20012029, 20590774.

*Correspondence to: Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, 54 Kawara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. Fax: +81-75-751-4303.

E-mail: maru@kuhp.kyoto-u.ac.jp

Received 16 October 2008; Accepted after revision 21 April 2009

DOI 10.1002/ijc.24565

Published online 11 May 2009 in Wiley InterScience (www.interscience.wiley.com).




FIGURE 1 – Parkin expression is induced in response to EGF stimulation in colon cells. (a) SW48, LoVo and HT29 cells were treated with human recombinant EGF (100 ng/ml) and total RNA was isolated 6 hr after EGF treatment. RT-PCR was performed using 1 μ g of each RNA sample as a template and oligonucleotide primers for human *Parkin* (upper panel) and β -actin (lower panel). (b) Time-course changes of *Parkin* mRNA expression after EGF stimulation. SW48 or HT29 cells were subjected to total RNA isolation immediately before and 6, 9, 12 and 18 hr after treatment with EGF. Real-time RT-PCR was performed using FAM-labeled probes specific for human *Parkin*. (c) SW48 or HT29 cells were treated with EGF (100 ng/ml) for 0, 8, 16 and 24 hr, followed by immunoblotting using anti-Parkin antibody (upper panel) or anti- β -actin antibody (lower panel). (d) Dose-dependent effects of EGF on Parkin expression. Cell lysate was extracted from SW48 or HT29 cells 16 hr after the treatment with various concentrations of EGF (0, 10 and 100 ng/ml). Immunoblotting was performed using anti-Parkin antibody (upper panel) or anti- β -actin antibody (lower panel).

Quantitative real-time reverse transcription polymerase chain reaction

For the RT reaction, total RNA was reverse-transcribed into cDNA using the Superscript III first strand synthesis system (Invitrogen).²³ The oligonucleotide primers used in this study are shown in Supplemental Table I. PCR amplification was performed using Takara Ex Taq DNA polymerase (Takara, Tokyo, Japan). Quantification of gene expression was performed by quantitative real-time RT-PCR using a 7300 Real-Time PCR system (PE Applied Biosystems, Foster City, CA). To assess the quantity of isolated RNA, as well as the efficiency of cDNA synthesis, target cDNAs were normalized to the endogenous mRNA levels of the housekeeping reference gene, *18s ribosomal RNA (18s rRNA)*.²³ For simplicity, the expression levels of the target gene were expressed relative to those of the control specimen.

Detection and subcloning of alternatively spliced Parkin

The oligonucleotide primers for *Parkin* were designed to amplify the whole coding sequences of human *Parkin* gene shown in Supplemental Table I. All PCR products were analyzed by electrophoresis in 1.2% agarose gels stained with ethidium bromide. Subcloning of purified DNA was performed by inserting the cDNA fragment into the BamHI-EcoRI sites of pcDNA3-Myc.²⁴

Immunoblotting analysis

Protein samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 10% (w/v) polyacrylamide gels and subjected to immunoblotting analysis as described previously.²⁵ Polyclonal antibodies against human Parkin and Akt were purchased from Chemicon International (CA) and Cell Signaling Technology (Danvers, MA), respectively. Monoclonal antibodies against cyclin E (E-4), c-Myc (9E10) and β -actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Sigma Chemical, respectively.

Patients and tissue specimens

Colon cancer tissue specimens were obtained from 43 patients treated between 2001 and 2004, at Kyoto University Hospital, as defined by TNM classification criteria.²⁶ Selection of patients enrolled in this study was based on the availability of a sufficient amount of tissue for analyses. The patients included 30 men and 13 women, with a mean \pm SD age of 65 ± 11.9 years (range, 36–82 years). All patients were treated by surgical resection of the involved segment of the colon. No prospective adjuvant chemotherapy was performed initially in all cases. Tissue specimens were frozen immediately in liquid nitrogen for RNA preparation, and were also fixed in 10% formalin, embedded in paraffin and subjected to histologic analyses. The study was approved by the




FIGURE 2 – HGF induces Parkin expression in human colon cells. (a) Time course of changes in Parkin protein expression. HT29 cells were harvested before (0 hr) and 18 and 24 hr after HGF (10 ng/ml) stimulation. (b) Dose-dependent effects of HGF on Parkin protein expression in colon cells. Cell lysate from HT29 or SW48 cells treated with HGF at the indicated concentration were subjected to immunoblotting using anti-Parkin (upper panel) or anti- β -actin (lower panel).

Kyoto University Graduate School and Faculty of Medicine Ethics Committee, and informed consent was obtained from all patients.

Results

Growth factor signaling induced Parkin expression in human colon cells

To gain insight into the role of Parkin in regulation of the cell cycle, we first examined *Parkin* gene expression in association with growth factor stimulation in cultured colon cells. First, we examined the effect of EGF on the expression of *Parkin* transcripts in several human colon cell lines. In unstimulated cells, only a trace amount of *Parkin* transcript was detected. In contrast, treatment of cells with EGF induced substantial *Parkin* expression (Fig. 1a). Quantitative RT-PCR analyses revealed that endogenous *Parkin* expression in both HT29 and SW48 cells markedly increased after EGF treatment, peaking 6 hr after treatment, whereas expression of the internal control *18s rRNA* transcripts was unchanged (Fig. 1b). Immunoblotting analysis using a specific antibody against human Parkin revealed that EGF induced time-dependent upregulation of Parkin protein in both cell lines, peaking 16 hr after treatment (Fig. 1c). Further, EGF stimulation induced a dose-dependent increase in Parkin expression (Fig. 1d). To examine whether growth factor stimulation generally enhances Parkin expression in human colon cells, we further analyzed Parkin expression in cells treated with hepatocyte growth factor (HGF). Parkin protein levels were markedly upregulated after treatment with HGF (Fig. 2a). Immunoblotting analyses revealed that HGF treatment induced a dose-dependent increase in Parkin expression with a maximum level obtained with 10 ng/ml in HT29

cells and 100 ng/ml in SW48 cells (Fig. 2b). Taken together, these findings suggested that endogenous Parkin expression is induced in response to growth factor stimulation in human colon cells.

EGF-induced Parkin expression was mediated by the Akt signaling pathway

The finding that EGF induced Parkin expression in colon cells led us to examine whether Parkin expression is mediated in a PI(3)K-Akt- or mitogen-activated protein kinase (MAPK)-dependent manner, because both of these pathways contribute to the expression and regulation of various genes downstream of EGF signaling.²⁷ First, we examined EGF-mediated Parkin expression in the presence of either a PI(3)K-Akt- or MAPK-inhibitor. Pretreatment with the MEK-inhibitor PD98059 had little effect on the expression of Parkin after EGF stimulation (Fig. 3a, upper panel). In contrast, the PI(3)K inhibitor wortmannin significantly attenuated EGF-mediated Parkin upregulation in HT29 cells (Fig. 3a, lower panel), suggesting that EGF-induced Parkin expression is mainly regulated by the PI(3)K-Akt-dependent signaling pathway. To further clarify whether Akt is involved in EGF-mediated Parkin expression, we examined the effects of the wild-type or dominant-negative form of Akt on Parkin expression. Quantitative RT-PCR analyses revealed that endogenous *Parkin* transcription was upregulated in colonic cells expressing wild-type *Akt* (Fig. 3b). Similarly, Parkin protein expression levels were significantly upregulated in the cells with wild-type *Akt* expression (Fig. 3c). In contrast, EGF-induced Parkin protein expression was almost completely abolished by co-production of the dominant-negative form of *Akt* (Fig. 3d). Taken together, these findings suggest that the EGF-mediated induction of Parkin expression in human colon cells is mainly achieved through the PI(3)K-Akt-signaling pathway.

Parkin induced proteolytic degradation of cyclin E protein in colon cells

To determine whether growth factor-mediated Parkin expression is involved in cell cycle regulation in colonic epithelial cells, we examined the expression levels of cyclin E protein in association with Parkin expression, because cyclin E is a putative substrate of Parkin-mediated proteasomal degradation in neurons.⁷ Immunoblotting analyses revealed that cyclin E protein expression in HT29 cells increased in response to EGF treatment, and peaked 18 hr after stimulation. At 20 hr after EGF stimulation, when EGF-mediated Parkin protein expression was at its peak, the expression levels of cyclin E protein were substantially reduced (Fig. 4a). Scanning densitometry analysis using the LAS-3000 imaging system (FujiFilm, Tokyo, Japan) revealed a more than 2-fold increase in the relative amount of Parkin after EGF stimulation. To examine whether Parkin degrades cyclin E in colon cells, HT29 cells were transfected with expression plasmid encoding wild-type *Parkin* or defective *Parkin* lacking E3 activity.² We first confirmed that the expression of the wild-type *Parkin* resulted in little change in the *cyclin E* mRNA expression levels in HT29 cells (Fig. 4b). In contrast, immunoblotting analyses revealed that expression levels of endogenous cyclin E protein were significantly reduced in the presence of wild-type *Parkin*, whereas defective *Parkin* had no effect on the expression levels of cyclin E protein (Fig. 4c). We also confirmed that the Parkin-mediated reduction of cyclin E protein expression was reversed by treatment with a proteasome inhibitor (Fig. 4d). Similarly, the downregulation of cyclin E protein in association with EGF-mediated Parkin expression was suppressed in cells treated with a proteasome inhibitor (Fig. 4e). Immunoprecipitation assay revealed that the pretreatment of cells expressing *Parkin* with the proteasome inhibitor MG132 accelerated the ubiquitination of cyclin E in these cells when compared with control cells, suggesting that cyclin E becomes a target of Parkin E3 ubiquitin ligase in colonic cells. (Supplemental Fig. 1). To clarify whether the reduction of cyclin E protein levels in the late phase of EGF stimulation was due to the upregulated Parkin protein, we knocked down the endogenous Parkin protein by transfecting a *Parkin*-specific siRNA and




FIGURE 3 – EGF-mediated Parkin expression is induced via the Akt-signaling pathway. (a) Effects of the MEK-inhibitor PD98059 or Akt-inhibitor wortmannin on EGF-mediated Parkin expression. HT29 cells were treated with PD98059 (10 μ M) or wortmannin (1 μ M) for 30 min, and further subjected to EGF (100 ng/ml) stimulation for 18 hr. Cell lysates were probed with anti-Parkin (upper panel) or anti- β -actin (lower panel) antibodies. (b,c) HT29 cells were transfected with plasmid for the expression of wild-type human Akt [Akt(+)] or with a control vector [Akt(-)]. After 18 hr, lysates of the transfected cells were subjected to quantitative RT-PCR analyses (b) or immunoblotting (c) with anti-Parkin (upper panel), anti-Akt (Akt; upper middle panel), anti-phospho Akt (lower middle panel), or anti- β -actin (lower panel) antibodies. (d) Expression plasmids encoding a dominant-negative form of human Akt (DN) or a control vector (CTR) were transfected into HT29 cells and then treated with EGF (100 ng/ml) for 18 hr. Each sample was harvested and the extracted cell lysates were probed with anti-Parkin (upper panel), anti-Akt (Akt; middle panel) or anti- β -actin (lower panel) antibodies.




FIGURE 4

assessed the time-course changes of the cyclin E protein expression in the colon cells. Knockdown of endogenous *Parkin* by siRNA resulted in the consistent upregulation of cyclin E protein after the treatment with EGF (Fig. 4f). These findings suggest that *Parkin* contributes to the proteolytic degradation of cyclin E protein in human colon cells.

Alternative splicing isoforms of Parkin with loss of cyclin E proteolysis were dominantly expressed in human colorectal cancers

The findings that EGF stimulation induced *Parkin* expression followed by the degradation of cyclin E protein suggested that *Parkin* exerts negative feedback regulation of proliferation signaling in epithelial cells. To clarify the functional significance of the *Parkin* defect in tumorigenesis, we investigated the expression profiles of *Parkin* in clinical specimens of human colorectal cancer tissues. To amplify the *Parkin* transcript, we designed a primer set spanning all of the exons of the *Parkin* gene. First, we confirmed that the signal amplified by this primer set corresponded to the expected size in normal colonic tissues. In contrast, 18 of 43 (42%) human colorectal cancers predominantly expressed *Parkin* transcripts that were smaller than expected (Fig. 5a). To determine the internal structure of these products, all amplified fragments were subcloned for further sequence analyses. All signals with a smaller sequence size corresponded to the *Parkin* transcript with the deletion of several exons spanning from exon 3 to exon 6 (Fig. 5b), indicating that aberrant and alternative splicing of the *Parkin* gene occurs in human colorectal cancers. In support of the results obtained from the analyses on human clinical specimens, we found predominant expression of alternatively spliced *Parkin* in DLD1 colon cancer cells *in vitro* (Supplemental Fig. 2). DLD1 cells expressed a *Parkin* transcript lacking exons 3 to 5 and exons 7 and 8, while HT29 colon cancer cells expressed wild-type *Parkin* predominantly. Immunoblotting confirmed the expression of the alternatively spliced *Parkin* in the lysate of DLD1 cells.

To determine whether the tumor-specific isoforms of alternatively spliced *Parkin* are involved in cell cycle deregulation, we examined whether splicing variants of *Parkin* expressed in human




FIGURE 5 – Alternatively spliced isoforms of *Parkin* transcripts were expressed in human colorectal cancers. (a) Total RNA was extracted from tumor (T) or non-tumorous (NT) regions of the colon tissues of patients with colorectal cancers. *Parkin* transcripts were determined by RT-PCR using primer sets for the amplification of full-length *Parkin* mRNA. Representative results of the gel electrophoresis of the amplified fragments from 5 patients with colorectal cancers are shown (case #A–#E). Black arrowhead indicates the fragment size of 1500 bp, corresponding to whole *Parkin* sequences of the expected size. Shorter fragments derived from *Parkin* amplification are indicated with white arrowheads. (b) Schematic presentation of alternatively spliced isoforms of *Parkin* expressed in colorectal cancers. The values in the schema indicate the exon number of the human *Parkin* gene. UBL, ubiquitin-like; UPD, unique *Parkin* domain; RING, really interesting new gene; IBR, in-between Ring; n = number of cases. (c) Alternative spliced *Parkin* proteins lacked proteolytic activity for cyclin E protein, 293T cells were transfected with expression plasmid encoding wild-type *Parkin* (Wt), various alternatively spliced isoforms of *Parkin* subcloned from the colon of cancer patients or a control vector (CTR). Cell lysates were prepared and subjected to immunoblotting using anti-myc (upper panel), anti-cyclin E (middle panel) or anti- β -actin (lower panel) antibodies. Quantification of the results of Western blotting was carried out by scanning densitometry analysis.

FIGURE 4 – *Parkin* expression triggers proteolysis of cyclin E protein in colon cells. (a) Time-course changes of the *Parkin* and cyclin E protein expression after EGF stimulation. HT29 cells were treated with EGF (100 ng/ml) at the indicated time points. Cell lysate was extracted and subjected to immunoblotting using anti-*Parkin* (upper panel), anti-cyclin E (middle panel) or anti- β -actin (lower panel) antibodies. Quantification of the results of Western blotting was carried out by scanning densitometry analysis using the LAS-3000 imaging system. (b,c) 293T cells were transfected with the expression plasmids encoding wild-type human *Parkin*, mutant *Parkin* lacking exon 3-4 (Δ -*Parkin*) or control vectors. (b) Total RNA extracted from the cells transfected with control vector (CTR) or wild-type *Parkin* expression plasmid was subjected to semiquantitative RT-PCR analyses using primers specific for *Parkin* (upper panel), cyclin E (middle panel) or β -actin (lower panel). (c) Lysates were also prepared from the transfected cells and immunoblotting was performed using anti-*Parkin* (upper panel), anti-cyclin E (middle panel) or anti- β -actin (lower panel) antibodies. (d) HT29 cells were treated with a proteasome inhibitor MG132 (10 μ M) for 1 hr, followed by the transfection with expression plasmid encoding the wild-type *Parkin*. Immunoblotting was performed using anti-*Parkin* (upper panel), anti-cyclin E (middle panel) or anti- β -actin (lower panel) antibodies. (e) HT29 cells were treated with EGF for 22 hr in the presence or absence of MG132 (10 μ M). Endogenous *Parkin*, cyclin E and β -actin protein expression was detected by immunoblotting analyses using anti-*Parkin* (upper panel), anti-cyclin E (middle panel) or anti- β -actin (lower panel) antibodies. (f) SW48 cells were transfected with siRNA targeting *Parkin* (siParkin) or control (CTR) siRNA for 24 hr, followed by treatment with EGF (100 ng/ml) for the additional indicated times. The cell lysates were subjected to immunoblot analyses to determine the protein production levels of anti-*Parkin* (upper panel), anti-cyclin E (middle panel) or anti- β -actin (lower panel).

colorectal cancer tissues were capable of inducing the proteolytic degradation of the cyclin E protein *in vitro*. We subcloned representative alternative splicing isoforms of *Parkin* from colorectal cancer tissues and constructed expression plasmids encoding the tumor-specific *Parkin* variants, including those lacking exons 3-4,

exons 3–5 and exons 3–6. We confirmed that the induction of wild-type *Parkin* reduced endogenous cyclin E protein expression. In contrast, there were slight upregulation in the expression levels of cyclin E protein in cells expressing any of the tumor-specific splicing isoforms of *Parkin* examined (Fig. 5c). In addition, we found that immunoreactivity for Ki67 in cells expressing *Parkin* splicing variants was substantially stronger than in cells expressing wild-type *Parkin* (Supplemental Fig. 3). These findings indicate that the alternative splicing of the *Parkin* gene might contribute to the accumulation of cyclin E protein, leading to the deregulation of cell-cycle progression in colorectal cancers.

Discussion

Parkin is an E3 ubiquitin ligase that belongs to the RING-finger family. Cyclin E may be a putative *Parkin* substrate.⁷ In contrast to the intensive research of *Parkin* in neurons, little is known about the transcriptional regulation of *Parkin* in human epithelial cells or the role of *Parkin* in cell cycle regulation. We, recently, reported that *Parkin*-deficient mice lacking exon 3 of the *Parkin* gene are susceptible to liver carcinogenesis, providing the first evidence that *Parkin* is a tumor suppressor gene.¹⁹ Consistent with our findings, a high frequency of loss of heterozygosity or deletions spanning the *Parkin* gene has been detected in various human cancers.^{9,18} In the present study, we demonstrated that *Parkin* expression is induced in response to growth signaling, and is involved in the proteolytic degradation of cyclin E protein in colonic epithelial cells.

EGF is implicated in the growth regulation of a variety of epithelial cells.²⁷ Enhanced EGF signaling is involved in the pathogenesis and progression of various human cancers.^{28,29} Of note, frequent overexpression of EGF receptors is observed in human colorectal cancer cells, and therefore, EGF signaling pathways have emerged as promising targets for anticancer therapy in the treatment of colorectal cancers.^{30,31} The present findings suggested that the downregulation of cyclin E protein in the late phase of EGF stimulation was attributable to the upregulation of *Parkin* in colon cells. These findings support the possibility that *Parkin* may be involved in a negative feedback regulation of the EGF-mediated proliferation signaling in colonic cells.

The *Parkin* gene contains 12 exons and is transcribed into a 457 amino acid protein. Functional domains within the *Parkin* protein include an amino-terminal ubiquitin-like (UBL) domain and the cysteine-rich unique *Parkin* domain (UPD) followed by 2 really interesting new gene (RING) fingers.³² We identified various alternatively spliced isoforms of *Parkin* in human colorectal cancers. Alternative splicing of *Parkin* in colorectal cancers resulted in the loss of various exons spanning exon 3 to exon 6, the region corresponding to the UPD. Notably, these alternatively spliced isoforms were defective in their ability to induce proteolytic degradation of cyclin E protein. Interestingly, point mutations of the *Parkin* gene in autosomal recessive juvenile Parkinsonism patients were clustered in the UBL, UPD and RING-finger motifs.³² Thus, our findings support the idea that all of the structural elements, including UPD, are essential for the functional integrity of *Parkin*.

Alternative splicing is a biologic event whereby identical precursor mRNA is spliced in different ways, contributing to the generation of protein diversity. Alternative splicing is a widely observed

phenomenon in the developmental process under physiologic conditions.³³ Recent studies suggest that alternative splicing is crucially linked to the development of cancer.³⁴ Indeed, many cancer-specific isoforms of tumor-related genes produced by alternative splicing have been identified in several human tumors.^{34,35} The most studied alternatively spliced gene in cancers might be *CD44*, in which inclusion of variable exons correlates with tumor development and metastasis.³⁶ It was shown that phosphorylation of the nuclear RNA binding protein Sam68 activated by growth signaling regulates alternative splicing of variable exon 5 of the *CD44* gene in lymphoma cells.³⁷ The findings of the present study indicated that various alternative splicing isoforms of the *Parkin* gene were dominantly expressed in a considerable number of human colorectal cancers. The molecular mechanisms responsible for the production of different splicing variants, however, is unclear, but cancer-specific changes in the splicing pattern have been reported in various genes without mutations in cis-acting splicing elements, suggesting that alternative splicing in tumor tissues may be due to changes in the trans-acting splicing regulators.³⁵

The interaction of transiently expressed cyclins with cyclin-dependent kinases (CDK) permits cell cycle progression. Cyclin E, an activator of Cdk2, is a G₁ cyclin necessary for the transition from the G₁ to S phase of the normal cell cycle.³⁸ Cyclin E-CDK2 activity is regulated during the cell cycle and peaks around the time of S-phase entry.^{39,40} This periodicity results from changes in cyclin E abundance, and cyclin E levels are normally tightly regulated so that peak cyclin E-Cdk2 kinase activity occurs only for a short time near the G₁/S boundary.⁴¹ Cyclin E abundance is regulated by E2F-dependent cyclin E transcription and cyclin E degradation is regulated by the ubiquitin-proteasome system. Cyclin E overexpression, however, is observed in a broad spectrum of human malignancies, including colorectal cancer, suggesting that proper regulation of cyclin E is important for the preservation of normal cellular functions.⁴² Indeed, overexpression of the cyclin E protein has been linked to shortening of the G₁ phase of the cell cycle,⁴³ enhanced cell proliferation⁴⁴ and induction of chromosomal instability.^{45,46} Our present findings revealed that human colorectal cancers expressed various *Parkin* isoforms that lack the ability to degrade cyclin E protein. We also confirmed that the expression of the alternatively spliced variants of *Parkin* identified in the tumor tissues resulted in the accumulation of cyclin E protein in the cultured colon cells.

In conclusion, the findings of the present study demonstrate that *Parkin* is transcriptionally regulated in a growth factor stimulation-dependent manner and is involved in the regulation of cyclin E expression, and suggest that alternative splicing of the *Parkin* gene contributes to enhanced colon cell proliferation, leading to the progression of colorectal cancers. Further analyses are required to clarify the mechanism of tumor-specific alternative splicing of *Parkin* and the prevalence of the *Parkin* isoforms that lack cyclin E-proteolysis activity in other types of human cancers.

Acknowledgements

The authors are grateful to Dr. H. Kubo for supplying the clinical specimens.

References

- Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. *Nat Genet* 2000;25:302–5.
- Imai Y, Soda M, Takahashi R. Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. *J Biol Chem* 2000;275:35661–4.
- Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CD95. *Proc Natl Acad Sci USA* 2000;97:13354–9.
- Wang M, Suzuki T, Kitada T, Asakawa S, Minoshima S, Shimizu N, Tanaka K, Mizuno Y, Hattori N. Developmental changes in the expression of parkin and UbcR7, a parkin-interacting and ubiquitin-conjugating enzyme, in rat brain. *J Neurochem* 2001;77: 1561–8.
- Imai Y, Takahashi R. How do Parkin mutations result in neurodegeneration? *Curr Opin Neurobiol* 2004;14:384–9.
- Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. *Cell* 2001; 105:891–902.

7. Staropoli JF, Mcdermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. *Neuron* 2003;37:735-49.
8. Farrer MJ. Genetics of Parkinson disease: paradigm shifts and future prospects. *Nat Rev Genet* 2006;7:306-18.
9. Saito S, Sirahama S, Matsushima M, Suzuki M, Sagae S, Kudo R, Saito J, Noda K, Nakamura Y. Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27. *Cancer Res* 1996;56:5586-9.
10. Tibiletti MG, Bernasconi B, Furlan D, Riva C, Trubia M, Buraggi G, Franchi M, Bolis P, Mariani A, Frigerio L, Capella C, Taramelli R. Early involvement of 6q in surface epithelial ovarian tumors. *Cancer Res* 1996;56:4493-8.
11. Orphanos V, McGown G, Hey Y, Thorncroft M, Santibanez-Koref M, Russell SE, Hickey I, Atkinson RJ, Boyle JM. Allelic imbalance of chromosome 6q in ovarian tumours. *Br J Cancer* 1995;71:666-9.
12. Rodriguez C, Causse A, Ursule E, Theillet C. At least five regions of imbalance on 6q in breast tumors, combining losses and gains. *Genes Chromosomes Cancer* 2000;27:76-84.
13. Morita R, Saito S, Ishikawa J, Ogawa O, Yoshida O, Yamakawa K, Nakamura Y. Common regions of deletion on chromosomes 5q, 6q, and 10q in renal cell carcinoma. *Cancer Res* 1991; 51:5817-20.
14. Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. *Oncogene* 2000;19:1572-8.
15. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR, Fishel R, Croce CM, et al. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. *Clin Cancer Res* 2004;10:2720-4.
16. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, Mcadams H, Trapasso F, Drusco A, Shimizu M, Masciullo V, D'andrilli G, Scambia G, et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. *Proc Natl Acad Sci USA* 2003;100:5956-61.
17. Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, Klein C, Smith DI. Alterations in the common fragile site gene Parkin in ovarian and other cancers. *Oncogene* 2003;22:8370-8.
18. Wang F, Denison S, Lai JP, Phillips LA, Montoya D, Kock N, Schule B, Klein C, Shridhar V, Roberts LR, Smith DI. Parkin gene alterations in hepatocellular carcinoma. *Genes Chromosomes Cancer* 2004;40:85-96.
19. Fujiwara M, Marusawa H, Wang HQ, Iwai A, Ikeuchi K, Imai Y, Kataoka A, Nukina N, Takahashi R, Chiba T. Parkin as a tumor suppressor gene for hepatocellular carcinoma. *Oncogene* 2008;27:6002-11.
20. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, See-llig S, Kononen J, Mihatsch MJ, Dirnhofer S, Sauter G. Cyclin E overexpression and amplification in human tumours. *J Pathol* 2003;200:375-82.
21. Sutter T, Dansranjav T, Lubinski J, Debnjak T, Giannakudis J, Hoang-Vu C, Dralle H. Overexpression of cyclin E protein is closely related to the mutator phenotype of colorectal carcinoma. *Int J Colorectal Dis* 2002;17:374-80.
22. Seimi SK, Seinosuke K, Tsuyoshi S, Tomomi U, Tetsuaki H, Miki K, Ryuji T, Kenji I, Mitsuhiro Y. Glycogen synthase kinase-3beta is involved in the process of myocardial hypertrophy stimulated by insulin-like growth factor-1. *Circ J* 2004;68:247-53.
23. Matsumoto Y, Marusawa H, Kinoshita K, Endo Y, Kou T, Morisawa T, Azuma T, Okazaki IM, Honjo T, Chiba T. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. *Nat Med* 2007;13:470-6.
24. Iwai A, Marusawa H, Matsuzawa S, Fukushima T, Hijikata M, Reed JC, Shimotohno K, Chiba T. Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates beta-catenin activity in a p53-dependent manner. *Oncogene* 2004;23:7593-600.
25. Endo Y, Marusawa H, Kinoshita K, Morisawa T, Sakurai T, Okazaki IM, Watahi K, Shimotohno K, Honjo T, Chiba T. Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. *Oncogene* 2007;26:5587-95.
26. Sobin LH, Wittekind C. TNM classification of malignant tumor, 6th edn. New York: Wiley, 2002.
27. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene* 2006;366:2-16.
28. Yasui W, Sumiyoshi H, Hata J, Kameda T, Ochiai A, Ito H, Tahara E. Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. *Cancer Res* 1988;48:137-41.
29. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncol Hematol* 1995;19:183-232.
30. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337-45.
31. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. *Cancer Res* 1999;59:1236-43.
32. Kahle PJ, Haass C. How does parkin ligate ubiquitin to Parkinson's disease? *EMBO Rep* 2004; 5:681-5.
33. Venables JP. Alternative splicing in the testes. *Curr Opin Genet Dev* 2002;12:615-19.
34. Venables JP. Aberrant and alternative splicing in cancer. *Cancer Res* 2004;64:7647-54.
35. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. *J Cell Sci* 2006;119:2635-41.
36. Stickeler E, Kittrell F, Medina D, Berget SM. Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. *Oncogene* 1999;18:3574-82.
37. Matter N, Herrlich P, Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. *Nature* 2002;420:691-5.
38. Sherr CJ. G1 phase progression: cycling on cue. *Cell* 1994;79:551-5.
39. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. *Science* 1992;257:1958-61.
40. Koff A, Giordano A, Desai D, Yamashita K, Harper JW, Elledge S, Nishimoto T, Morgan DO, Franza BR, Roberts JM. Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle. *Science* 1992;257:1689-94.
41. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. *Curr Opin Cell Biol* 2000;12:676-84.
42. Keyomarsi K, Conte D, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. *Oncogene* 1995;11:941-50.
43. Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. *Science* 1993;259:1908-12.
44. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. *Oncogene* 2004;23:2648-57.
45. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. *Cancer Res* 2004;64:3198-208.
46. Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. *Nature* 1999;401:297-300.

available at www.sciencedirect.comwww.elsevier.com/locate/brainres
**BRAIN
RESEARCH**
Research Report

Chronic cerebral hypoperfusion accelerates amyloid β deposition in APPSwInd transgenic mice

Hiroshi Kitaguchi^a, Hidekazu Tomimoto^{a,*}, Masafumi Ihara^a, Masunari Shibata^a, Kengo Uemura^a, Rajesch N. Kalaria^d, Takeshi Kihara^c, Megumi Asada-Utsugi^b, Ayae Kinoshita^b, Ryosuke Takahashi^a

^aDepartment of Neurology, Kyoto University, Sakyo-ku, Kyoto, 606-8504, Japan

^bSchool of Health Sciences, Graduate School of Medicine, Kyoto University, Sakyo-ku, Kyoto, 606-8504, Japan

^cDepartment of Neuroscience for Drug Discovery, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto, 606-8501, Japan

^dInstitute for Health and Ageing, University of Newcastle upon Tyne, Newcastle General Hospital, Westgate Road, Newcastle-upon-Tyne, NE4 6BE, UK

ARTICLE INFO
Article history:

Accepted 22 July 2009

Available online 30 July 2009

Keywords:

Cerebral ischemia

Amyloid β

Amyloid precursor protein

Transgenic mouse

ABSTRACT

Chronic cerebral ischemia may accelerate clinicopathological changes in Alzheimer's disease. We have examined whether chronic cerebral hypoperfusion accelerates amyloid β deposition in amyloid protein precursor transgenic (APP-Tg) mouse. At 5, 8, and 11 months of age, C57Bl/6J male mice overexpressing a mutant form of the human APP bearing the both Swedish (K670N/M671L) and the Indiana (V717F) mutations (APPSwInd) and their littermates were subjected to either sham operation or bilateral carotid artery stenosis (BCAS) using microcoils with an internal diameter of 0.18 mm (short-period group). One month after the sham operation or BCAS, these animals were examined by immunohistochemistry for glial fibrillary acidic protein, amyloid β_{1-40} ($A\beta_{1-40}$), amyloid β_{1-42} ($A\beta_{1-42}$), as well as Western blotting and filter assay for $A\beta$. Another batch of the littermates of APPSwInd mice were subjected to either sham operation or BCAS at 3 months and were examined in the same manner after survival for 9 months (long-period group). In the BCAS-treated group, the white matter was rarefied and astroglia was proliferated. Amyloid β_{1-40} immunoreactivity was found in a few axons in the white matter after BCAS, whereas $A\beta_{1-42}$ was accumulated in the scattered cortical neurons and the axons at ages of 6 months and thereafter in the short- and long-period groups. In the neuropil, both $A\beta_{1-40}$ and $A\beta_{1-42}$ were deposited in the sham-operated and BCAS-treated mice at ages of 9 and 12 months. There were no differences between the short-period group at ages of 12 months and the long-period group. Filter assay showed an increase of $A\beta$ fibrils in the extracellular enriched fraction. Taken together, chronic cerebral hypoperfusion increased $A\beta$ fibrils and induced $A\beta$ deposition in the intracellular compartment and, therefore, may accelerate the pathological changes of Alzheimer's disease.

© 2009 Elsevier B.V. All rights reserved.

* Corresponding author. Present address: Department of Neurology, Graduate School of Medicine, Mie University, 2-174 Edobashi, Tsu, 514-8507, Japan. Fax: +81 59 231 5107.

E-mail address: tomimoto@clin.medic.mie-u.ac.jp (H. Tomimoto).